Linked Life Data

2574549

Source:http://linkedlifedata.com/resource/pubmed/id/2574549

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6 Pt 1
pubmed:dateCreated
1990-1-23
pubmed:abstractText
Astemizole is a nonsedative H1-antagonist. It was used in a randomized double-blind, placebo-controlled in-season trial to assess its efficacy in patients with perennial allergic rhinitis showing seasonal exacerbations. By the last (6th) week of the study, the mean overall symptomatology, as rated by a global composite score, was significantly mitigated in the astemizole-treated group (18 patients) compared with their first week's global composite score (P less than .01). No such improvement was observed in the placebo-treated group (18 patients). Side effects were not appreciable throughout this short-term study. We conclude that astemizole is effective in the treatment of patients with perennial allergic rhinitis showing seasonal enhancement of symptoms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0003-4738
pubmed:author
pubmed:issnType
Print
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
493-4
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Astemizole in perennial allergic rhinitis with seasonal exacerbations: a placebo-controlled double-blind study.
pubmed:affiliation
Clinical Immunology and Allergy Unit, Edith Wolfson Medical Center, Holon, Israel.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial